» Articles » PMID: 9741353

Modulation of Alloimmune Response in Vitro by an IgM-enriched Immunoglobulin Preparation (Pentaglobin)

Overview
Journal Immunology
Date 1998 Sep 19
PMID 9741353
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The mode of action of intravenous immunoglobulins (IVIG) in autoimmune and immunoregulatory disorders is still poorly understood. In vitro, direct effects of IVIG on cytokine release and on cytokine receptors have been described, as well as naturally occurring, neutralizing anticytokine antibodies. The aim of our study was to investigate whether the enrichment in IgM and IgA would have any impact on the in vitro immunomodilatory capacity of IVIG. The preparation tested (Pentaglobin) contains 76% IgG and 12% IgM and IgA, respectively. We could demonstrate a significant inhibition of alloantigen-induced proliferation in the mixed lymphocyte reaction (MLR) even at a Pentaglobin concentration of 1.0 mg/ml. About 10-fold higher concentrations of standard 7S IVIG containing only trace amounts of IgM and IgA were necessary to achieve equivalent suppression of the alloimmune response. Similarly, phytohaemagglutinin (PHA)-induced lymphocyte proliferation was more effectively inhibited by Pentaglobin than by standard 7S IVIG. Cytokine analyses in culture supernatants of MLR provide evidence that Pentaglobin not only modulates interleukin-2 (IL-2), which has already been observed with standard 7S IVIG, but, moreover, modulates interferon-gamma production with a subsequent impact on monocyte-derived tumour necrosis factor-alpha and IL-6 release. Based on these results we conclude that in vitro the IgM- and IgA-enriched Pentaglobin has a more potent immunomodulatory capacity than conventionally used standard 7S IVIG.

Citing Articles

A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases.

Bohlander F Front Immunol. 2023; 14:1127339.

PMID: 37051237 PMC: 10083398. DOI: 10.3389/fimmu.2023.1127339.


Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study.

Rahmel T, Kraft F, Haberl H, Achtzehn U, Brandenburger T, Neb H Crit Care. 2022; 26(1):204.

PMID: 35799196 PMC: 9260992. DOI: 10.1186/s13054-022-04059-0.


The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin.

Bohlander F, Weissmuller S, Riehl D, Gutscher M, Schuttrumpf J, Faust S Biomedicines. 2021; 9(12).

PMID: 34944644 PMC: 8698729. DOI: 10.3390/biomedicines9121828.


The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia.

Bestwick J, Sharman M, Whitley N, Kisielewicz C, Skelly B, Tappin S J Vet Intern Med. 2021; 36(1):78-85.

PMID: 34779044 PMC: 8783326. DOI: 10.1111/jvim.16315.


Sepsis-Pathophysiology and Therapeutic Concepts.

Jarczak D, Kluge S, Nierhaus A Front Med (Lausanne). 2021; 8:628302.

PMID: 34055825 PMC: 8160230. DOI: 10.3389/fmed.2021.628302.


References
1.
Hurez V, Kazatchkine M, Vassilev T, Ramanathan S, Pashov A, Basuyaux B . Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood. 1997; 90(10):4004-13. View

2.
Nachbaur D, Herold M, Eibl B, Glassl H, Schwaighofer H, Huber C . A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology. 1997; 90(2):212-8. PMC: 1456751. DOI: 10.1046/j.1365-2567.1997.d01-2148.x. View

3.
Huber C, Fink U, Leibold W, Schmalzl F, Peterson P, Klareskog L . The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol. 1981; 127(2):726-31. View

4.
Newburger J, Takahashi M, Burns J, Beiser A, Chung K, Duffy C . The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315(6):341-7. DOI: 10.1056/NEJM198608073150601. View

5.
Holler E, Kolb H, Moller A, Kempeni J, Liesenfeld S, Pechumer H . Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990; 75(4):1011-6. View